CLINICAL STUDY WITH PRE-ALZHEIMER’S CONDITION

MMT to start First Clinical Study on Pre-Alzheimer’s (pre-ALZ) State

MMT has received IRB approval for the PCD=OO ALZ clinical study to evaluate the effectiveness of several particular medications / treatments in the preventative treatment of Pre-clinical Alzheimer’s disease (ALZ). These medications are approved by FDA for other indications and have shown promise in preventing the progression of Preclinical Alzheimer’s disease and / or of Alzheimer’s disease.

Typical Warning signs of Dementia

The PCD=OO ALZ clinical study will attempt to verify two recent and very critical concepts in ALZ Clinical Research.

  • It is possible to provide information which can help predict the future development of ALZ in a preclinical state in a cognitively normal but high risk individual at least 18-48 months before any symptoms of cognitive impairment.
  • Early treatment of these cognitively normal but high-risk persons with subclinical pre-ALZ may prevent or delay the occurrence and severity of ALZ.
The clinical study follows this general outline :

1. Identification of individuals who are cognitively normal but who are at high risk of developing ALZ in a 24-36 month period. MMT uses a combination of standard psychometric examinations to confirm the presence of both a normal cognitive state and the apo-e gene, before proceeding to the next steps. Individuals can use a number of online resources such as the SAGE Test to self-screen for cognitive impairment, or they can request their treating / primary care doctor PMD to perform the SAGE, MMSE or similar test. Their PMD physicians can arrange for apo e testing, which can be a simple in-office blood test.

The clinical study follows this general outline :

  • Take a test to verify a normal cognitive state,
  • Document a first degree relative has ALZ,
  • Document that you have the apo-e gene.
Case definition : High Risk for pre-ALZ
  • Normal screen for cognition, and
  • First degree relative with ALZ, and
  • Presence of apo e gene

or their PMD can contact MMT NeuroTech by email dhm@milmag.net for consideration of enrollment in this study. Neurologists, psychologists, Alzheimer treatment centers and other professionals interested in participating in this protocol are invited to contact MMT NeuroTech.by email dhm@milmag.net

2. In an individual who fits the above Definition of High Risk for pre-ALZ (insert or link to the popup), specific neuroimaging may be performed to confirm the presence of patterns that are highly correlated with the future development of Alzheimer’s within 18 to 24 months. The neuroimaging can be ordered thru your PMD. All cognitive and neuroimaging testing are also available as a separate service independent of the protocol. Please contact MMT NeuroTech by email dhm@milmag.net if interested.

3. Initiation of specific treatments thru your PMD which are designed to prevent the progression to clinical ALZ of high-risk but cognitively normal individuals.

4. Observation and testing with cognitive metrics and neuroimaging over a three year period to document the reduced rate of progression to ALZ disease in the treatment group.

5. Study participants will remain under the care of their PMD, and all testing and treatments will take place thru them.

6. Potential benefits for participation in this clinical study:

  • Determine if they are at high risk of developing clinical Alzheimer’s in the short term.
  • Verify that they are currently of normal cognitive status
  • Contribute to determining that it is possible to reverse the course of pre clinical Alzheimer’s and not be absolutely doomed to develop clinical ALZ MMT NeuroTech hopes that concerned individuals will self-test for the above case definition of pre-ALZ, and that they will then contact MMT NeuroTech ( dhm@milmag.net) for participation in this protocol.